文献速递中药与中成药合理使用中医内科

天舒胶囊抗血瘀作用机制:转录组学与网络药理学研究

Integrated transcriptomics and network pharmacology analyses reveal potential effective components and mechanism of Tianshu capsule against blood stasis.
PubMed 文献 · J Ethnopharmacol · 2026-10-09

本研究在斑马鱼血瘀模型中评价天舒胶囊的抗血瘀药理效应,并采用转录组学与网络药理学解析其分子机制与潜在有效成分。结果显示天舒胶囊可改善血流与血小板循环并下调凝血因子,鉴定出11种抗血瘀活性成分,预测parishin B、parishin C、parishin E和senkyunolide I可能作用于MMP13、HMOX1和MMP9等靶点。

要点

  • 天舒胶囊在斑马鱼血瘀模型中可增加血流速度、减少血细胞聚集并恢复血小板循环。
  • 转录组学提示mmp13a、hmox1a、mmp9及补体相关因子可能介导天舒胶囊抗血瘀效应。
  • 网络药理学与分子对接预测parishin B/C/E和senkyunolide I与MMP13、HMOX1、MMP9存在相互作用。

核心结论

  • 天舒胶囊在斑马鱼血瘀模型中具有抗血瘀药理效应,其机制可能通过调控mmp13a、hmox1a、mmp9及补体相关因子表达介导。
  • 共鉴定出11种成分具有抗血瘀活性,为天舒胶囊潜在质量标志物选择提供科学依据。

研究设计与样本

  • 研究采用苯肼诱导的转基因斑马鱼血瘀模型,利用高内涵成像系统评价天舒胶囊的抗血瘀效应。
  • 研究运用转录组学分析天舒胶囊的潜在机制,并结合网络药理学与分子对接预测血瘀相关靶点及成分-靶点相互作用。

主要发现

  • 天舒胶囊治疗显著增加血流速度、减少血细胞聚集并恢复血小板循环,同时显著下调凝血因子表达。
  • 转录组分析识别mmp13a、hmox1a、mmp9和补体相关因子(c3a.2、c3a.3)为可能介导天舒胶囊药理效应的候选靶点。
  • 共有11种成分表现出抗血瘀活性,网络药理学联合分子对接预测parishin B、parishin C、parishin E和senkyunolide I可能与MMP13、HMOX1和MMP9相互作用。

临床怎么用

  • 本研究为天舒胶囊抗血瘀作用的分子机制提供了实验依据,提示其可能通过调控mmp13a、hmox1a、mmp9及补体相关因子发挥效应。
  • 鉴定的11种抗血瘀活性成分及预测的parishin B/C/E和senkyunolide I与MMP13、HMOX1、MMP9的相互作用,可为后续质量标志物选择提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Blood stasis syndrome (BSS) is a pathological state associated with blood circulation disorders and vascular injury, which predisposes to cardiovascular diseases. Tianshu capsule (TS) is a Chinese patent medicine with properties of activating blood circulation and dredging meridians. However, its potential effective components and mechanism in BSS were incompletely understood. AIM OF THE STUDY: To investigate the pharmacological effect, molecular mechanism and potential effective components of TS in zebrafish blood stasis model. MATERIALS AND METHODS: Phenylhydrazine-induced blood stasis model was established in transgenic zebrafish to evaluate the anti-blood stasis effect of TS using the high-content imaging system. Transcriptome profiling was employed to dissect the potential mechanism of TS. Network pharmacology and molecular docking were applied to predict BSS-associated targets and component-target interactions for TS. RESULTS: TS treatment significantly increased blood flow velocity, reduced blood cell aggregation, and restored platelet circulation, while also markedly downregulating the expression of coagulation factors. Transcriptomic analysis identified mmp13a, hmox1a, mmp9 and complement-related factors (c3a.2, c3a.3) as candidate targets that may mediate the pharmacological effect of TS. A total of 11 components exhibited the anti-blood stasis activity, and network pharmacology combined with molecular docking further predicted that parishin B, parishin C, parishin E, and senkyunolide I may interact with MMP13, HMOX1 and MMP9. CONCLUSIONS: Our study provides new insights into the anti-blood stasis effect of TS, which is possibly mediated by regulating mmp13a, hmox1a, mmp9 and complement-related factors expression. A total of 11 components were identified as potential effective components responsible for the anti-blood stasis effect, thereby providing a scientific basis for the future selection of potential quality markers for TS.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li J, Xie P, Lu M, et al. Integrated transcriptomics and network pharmacology analyses reveal potential effective components and mechanism of Tianshu capsule against blood stasis. J Ethnopharmacol. 2026. PMID: 42854859. doi:10.1016/j.jep.2026.122436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。